Trending News

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

Supreme Court Eliminates Heightened Discrimination Standard Under Title VII

Cleaning the Cupboard—Six More Decisions in One Day, and a Largely Harmonious Court - SCOTUS Today

U.S. Supreme Court Holds Majority-Group Plaintiffs Are Not Subject to a Heightened Evidentiary Standard Under Title VII

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
Posted On Friday, May 09, 2025
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
Posted On Friday, May 09, 2025
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
Posted On Friday, May 09, 2025
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
Posted On Friday, May 09, 2025
Sanuwave Announces Q1 FY2025 Financial Results
Posted On Friday, May 09, 2025
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
Posted On Thursday, May 08, 2025
Keros Reinforces Commitment to Maximizing Stockholder Value
Posted On Thursday, May 08, 2025
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Posted On Thursday, May 08, 2025
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
Posted On Thursday, May 08, 2025
BioSyent Schedules First Quarter Earnings Release for May 15, 2025
Posted On Thursday, May 08, 2025
Galecto Reports First Quarter 2025 Operating and Financial Results
Posted On Thursday, May 08, 2025
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Posted On Thursday, May 08, 2025
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Posted On Thursday, May 08, 2025
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Posted On Thursday, May 08, 2025
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Posted On Thursday, May 08, 2025
PacBio Announces First Quarter 2025 Financial Results
Posted On Thursday, May 08, 2025
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Posted On Thursday, May 08, 2025
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
Posted On Thursday, May 08, 2025
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
Posted On Thursday, May 08, 2025
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
Posted On Thursday, May 08, 2025
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Posted On Thursday, May 08, 2025
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Posted On Thursday, May 08, 2025
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Posted On Thursday, May 08, 2025
Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress
Posted On Thursday, May 08, 2025
UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers
Posted On Thursday, May 08, 2025

Print